Efforts to optimize treatments to address critical challenges in treating idiopathic pulmonary fibrosis (IPF) has been given a boost by a more than CA$670,000 grant to support a collaborative project between Ceapro and academic researchers at McMaster…
Men who are active smokers and experience faster respiratory decline when diagnosed with idiopathic pulmonary fibrosis (IPF) are at greater risk to develop lung cancer, according to a study. Clinicians should be aware of this risk pattern in order to detect and treat lung cancer early in IPF patients, as…
Online forums have markedly altered how patients, caregivers, and healthcare professionals communicate and connect. Even when miles apart, individuals can establish supportive relationships, share experiences and information, and sometimes simply vent. Bionews Services, a leading online health, science, and research publication company, has been introducing its own…
Inflammatory bowel disease (IBD) increases the risk of developing idiopathic pulmonary fibrosis (IPF), particularly in male patients with Crohn’s disease, a large-scale population study shows. The study, “Increased Risk of Idiopathic Pulmonary Fibrosis…
Low body mass index (BMI) is a risk factor for nausea and diarrhea as side effects of Ofev (nintedanib) treatment in patients with idiopathic pulmonary fibrosis (IPF), a study has found. These results also suggest that lower performance status and a full starting dosage are risk factors…
Imagine living your whole life with a painful disease so rare that only 25 others worldwide have what you have. And that you’re one of just six such people who’ve made it to adulthood. Neena Nizar doesn’t have to imagine. The 41-year-old English professor at Metro Community College in Elkhorn,…
Impaired autophagy — cells’ self-cleansing process — in the lungs’ epithelial cells may activate their epithelial-mesenchymal transition (EMT), a process crucial to the progression of fibrosis, according to a new study. The finding  suggests that therapies targeting EMT may help halt fibrosis in idiopathic pulmonary fibrosis (IPF). The study, “…
N115, EmphyCorp‘s investigational non-steroidal nasal spray for the treatment of interstitial lung diseases (ILDs), has completed a Phase 3 clinical trial requested by the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) in patients with pulmonary fibrosis (PF). EmphyCorp’s proprietary…
Taking Esbriet (pirfenidone) to manage idiopathic pulmonary fibrosis (IPF) does not increase the risk of heart problems or interfere with commonly used cardiovascular medications, an analysis found. Results of the analysis were published in the journal Advances In Therapy in an article titled, “Cardiovascular Risks,…
People with idiopathic pulmonary fibrosis (IPF) and right heart dysfunction may benefit more from a therapy combining Ofev (nintedanib) with sildenafil than from Ofev alone in terms of cardiac health, according to data from a Phase 3 study. The study, “Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary…
Get regular updates to your inbox.
